These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33295445)

  • 1. Frequency and Reasons for Non-Administration and Suspension of Drugs During an Acute Coronary Syndrome Event. The ERICO Study.
    Santos RCO; Bensenor IM; Goulart AC; Lotufo PA; Santos IS
    Arq Bras Cardiol; 2020 Nov; 115(5):830-839. PubMed ID: 33295445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-To-Treatment of Acute Coronary Syndrome and Unit of First Contact in the ERICO Study.
    Santos RC; Goulart AC; Kisukuri AL; Brandão RM; Sitnik D; Staniak HL; Bittencourt MS; Lotufo PA; Bensenor IM; Santos IS
    Arq Bras Cardiol; 2016 Oct; 107(4):323-330. PubMed ID: 27849262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study.
    Pereira M; Araújo C; Dias P; Lunet N; Subirana I; Marrugat J; Capewell S; Bennett K; Azevedo A
    Eur J Prev Cardiol; 2014 Nov; 21(11):1401-8. PubMed ID: 23787795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the use of 4 recommended drug categories and patient perceptions of health status following an ACS event.
    Erickson SV; Rangarajan K; Kline-Rogers EM; Smith DE; Eagle KA
    J Manag Care Pharm; 2009 Sep; 15(7):533-42. PubMed ID: 19739876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre retrospective study to understand anti-platelet treatment patterns and outcomes of acute coronary syndrome patients in India (TRACE).
    Kaul U; Sethi KK; Dalal J; Parikh K; Hiremath MS; Mullasari AS; Nair T; Sandhu PS; Kotak B
    Indian Heart J; 2014; 66(3):334-9. PubMed ID: 24973840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
    Bi Y; Gao R; Patel A; Su S; Gao W; Hu D; Huang D; Kong L; Qi W; Wu Y; Yang Y; Turnbull F;
    Am Heart J; 2009 Mar; 157(3):509-516.e1. PubMed ID: 19249422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome.
    Melloni C; Alexander KP; Ou FS; LaPointe NM; Roe MT; Newby LK; Baloch K; Ho PM; Rumsfeld JS; Peterson ED
    Am J Cardiol; 2009 Jul; 104(2):175-81. PubMed ID: 19576342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry).
    Cheng CI; Chen CP; Kuan PL; Lei MH; Liau CS; Ueng KC; Wu CJ; Lai WT
    Clin Cardiol; 2010 Jun; 33(6):E40-8. PubMed ID: 20552592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS.
    Yang S; Cui C; Zhang J; Qiao R
    Clin Lab; 2016 Oct; 62(10):1911-1918. PubMed ID: 28164519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    Gurbel PA; Erlinge D; Ohman EM; Neely B; Neely M; Goodman SG; Huber K; Chan MY; Cornel JH; Brown E; Zhou C; Jakubowski JA; White HD; Fox KA; Prabhakaran D; Armstrong PW; Tantry US; Roe MT;
    JAMA; 2012 Nov; 308(17):1785-94. PubMed ID: 23117779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Yahia DH; Pereg D; Lishner M; Elis A
    Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Ebrahimi R; Dyke C; Mehran R; Manoukian SV; Feit F; Cox DA; Gersh BJ; Ohman EM; White HD; Moses JW; Ware JH; Lincoff AM; Stone GW
    J Am Coll Cardiol; 2009 May; 53(21):1965-72. PubMed ID: 19460609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
    Cuisset T; Deharo P; Quilici J; Johnson TW; Deffarges S; Bassez C; Bonnet G; Fourcade L; Mouret JP; Lambert M; Verdier V; Morange PE; Alessi MC; Bonnet JL
    Eur Heart J; 2017 Nov; 38(41):3070-3078. PubMed ID: 28510646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.